On this page you'll find access to more information on ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) and are provided with some materials that you can share with your patients.
THE USE OF THE ENERZAIR® BREEZHALER® DEVICE
This guide helps familiarise HCPs and patients on the use of the ENERZAIR® BREEZHALER® device
PATIENT INFORMATION BOOKLET ON THE ENERZAIR® DEVICE AND SENSOR
This booklet has been designed to help guide patients on the use of the ENERZAIR® BREEZHALER® device and Sensor
To order copies of this material, please contact a Novartis representative by clicking here.
ENERZAIR® BREEZHALER® STEP-BY-STEP INSTRUCTION GUIDE FOR PATIENTS
This step-by-step guide has been designed to show patients how to use their ENERZAIR® BREEZHALER® inhaler correctly, to ensure they receive the correct dosage
To order copies of this material, please contact a Novartis representative by clicking here.
PODCAST
Our podcast series focuses on the unmet needs in asthma – Why do patients remain uncontrolled?1–6
Indication: ENERZAIR® BREEZHALER® is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.7
References
- Buhl R, et al. Respir Med 2020;162:105859.
- WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma. Date accessed: January 2021.
- Kerstjens HA, et al. N Engl J Med 2012;367:1198–207.
- Kerstjens HA, et al. Respir Med 2016;117:198–206.
- Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2014. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf. Date accessed: January 2021.
- ENERZAIR® BREEZHALER® Summary of Product Characteristics.